AMALY — SHARIAH COMPLIANCE REPORT
==================================
Symbol: AVXX
Report Date: 2026-04-17
Full Report: https://amaly.io/stock/AVXX

EXECUTIVE SUMMARY
------------------
Compliance Status: NON_COMPLIANT
Quality Rating: B
Description: AVXX, formerly AveXis Inc., a biotechnology company focused on gene therapy, was acquired by Novartis in 2018 and is no longer actively traded. Due to its delisted status and lack of current financial reporting, comprehensive Shariah screening is limited by data insufficiency. All major Shariah indices exclude AVXX, leading to a non-compliant classification. Business activities in medical research appear permissible, but verification is impossible without updated disclosures. Investors should avoid or monitor for any residual holdings, with no purification required based on available data.

Primary Compliance Concerns:
- Insufficient financial data preventing ratio calculations
- Delisted status leading to exclusion from Shariah indices
- Lack of transparency in post-acquisition operations
- Data gaps in business activity and subsidiary analysis

Purification Requirement: 0.00%
Index Inclusion: Not included in any major Shariah indices (S&P, MSCI, FTSE, DJIM)

KEY FINANCIAL METRICS
----------------------
Debt Ratio: 0.0%
Liquidity Ratio: 0.0%
Interest Income Ratio: 0.0%
Purification Required: 0.00%

INDEX INCLUSION STATUS
-----------------------
S&P Shariah: EXCLUDED
MSCI Islamic: EXCLUDED
DJIM: EXCLUDED
FTSE Shariah: EXCLUDED
Total: 0 of 4
Last Verified: 2025-11-30

REPORTING PERIOD
-----------------
Latest Annual Report: FY 2017
Latest Quarterly Data: Pre-acquisition Q4 2017 (no current data available post-2018 acquisition)
Trend Period: FY 2013 to FY 2017 (limited historical data)
Data Retrieved: 2026-02-20T00:00:00Z

---
Full interactive report: https://amaly.io/stock/AVXX
Provided by Amaly (https://amaly.io) — Shariah Compliant Stock Screener
Disclaimer: This data is for informational purposes only and does not constitute financial or religious advice.